Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial

Journal:

European Urology

Published:

2025-08-16

DOI:

10.1016/j.eururo.2025.07.019

Affiliations:

24

Authors:

23

Go to article

Institutions	Authors	Share
Lorraine Institute of Oncology (ICL), France	5.125000	0.22
Centre Henri Becquerel, France	1.041667	0.05
AP-HP Pitié-Salpêtrière Hospital, France	1.041667	0.05
Hôpital Saint-Louis, France	1.041667	0.05
Hopital Bretonneau Tours, France	1.041667	0.05
CHU de Poitiers, France	1.041667	0.05
Institute of Cancer Research (ICO), France	1.041667	0.05
Hospital Emile Muller, France	1.041667	0.05
UNICANCER Group, France	1.041667	0.05
Bergonié Cancer Institute, France	1.041667	0.05
Centre Eugène Marquis (CEM), France	1.041667	0.05
Centre Antoine-Lacassagne (CAL), France	1.041667	0.05
Centre Hospitalier Régional Universitaire de Nîmes (CHU de Nîmes), France	1.041667	0.05
Institut Jean Godinot, France	1.041667	0.05
Centre Léon Bérard (CLB), France	0.541667	0.02
Institut Mondor de Recherche Biomédicale (IMRB), France	0.541667	0.02
Curie Institute, France	0.541667	0.02
Institut de Recherche en Cancérologie de Montpellier (IRCM), France	0.541667	0.02
Institut du Cancer de Montpellier (ICM), France	0.541667	0.02
CHU Henri-Mondor, France	0.541667	0.02
Claudius Regaud Institute (ICR), France	0.541667	0.02
Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole), France	0.541667	0.02

Interested in Oncology and Carcinogenesis?